DESCRIPTION
Atracurium besylate is an intermediate-duration, nondepolarizing, skeletal muscle relaxant for intravenous administration. Atracurium besylate is designated as 2-(2-Carboxyethyl)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-veratrylisouquinolinium benzenesulfonate, pentamethylene ester. It has a molecular weight of 1243.49, and its molecular formula is C_{65}H_{82}N_{2}O_{18}S_{2}. The structural formula is:

![Structural formula of atracurium besylate]

Atracurium besylate is a complex molecule containing four sites at which different stereochemical configurations can occur. The symmetry of the molecule, however, results in only ten, instead of sixteen, possible different isomers. The manufacture of atracurium besylate results in these isomers being produced in unequal amounts but with a consistent ratio. Those molecules in which the methyl group attached to the quaternary nitrogen projects on the opposite side to the adjacent substituted-benzyl moiety predominate by approximately 3:1.

Atracurium Besylate Injection USP is a sterile, non-pyrogenic aqueous solution. Each mL contains 10 mg atracurium besylate. The pH is adjusted to 3.00 to 3.65 with benzenesulfonic acid. The multiple dose vial contains 0.9% benzyl alcohol added as a preservative. Atracurium besylate injection slowly loses potency with time at the rate of approximately 6% per year under refrigeration (5°C). Atracurium besylate injection should be refrigerated at 2°C to 8°C (36°F to 46°F) to preserve potency. Rate of loss in potency increases to approximately 5% per month at 25°C (77°F). Upon removal from refrigeration to room temperature storage conditions (25°C / 77°F), use atracurium besylate injection within 14 days even if rerefrigerated.

CLINICAL PHARMACOLOGY
Atracurium besylate is a nondepolarizing skeletal muscle relaxant. Nondepolarizing agents antagonize the neurotransmitter action of acetylcholine by binding competitively with cholinergic receptor sites on the motor end-plate. This antagonism is inhibited, and neuromuscular block reversed, by acetylcholinesterase inhibitors such as neostigmine, edrophonium, and pyridostigmine.

Atracurium can be used most advantageously if muscle twitch response to peripheral nerve stimulation is monitored to assess degree of muscle relaxation.

The duration of neuromuscular block produced by atracurium is approximately one-third to one-half the duration of block by d-tubocurarine, metocurine, and pancuronium at initially equipotent doses. As with other nondepolarizing neuromuscular blockers, the time to onset of paralysis decreases and the duration of maximum effect increases with increasing atracurium doses.

The ED_{95} (dose required to produce 95% suppression of the muscle twitch response with balanced anesthesia) has averaged 0.23 mg/kg (0.11 to 0.26 mg/kg in various studies). An initial atracurium dose of 0.4 to 0.5 mg/kg generally produces maximum neuromuscular block within 3 to 5 minutes of injection, with good or excellent intubation conditions within 2 to 2.5 minutes in most patients. Recovery from neuromuscular block (under balanced anesthesia) can be expected to begin approximately 20 to 35 minutes after injection. Under balanced anesthesia, recovery to 25% of control is achieved approximately 35 to 45 minutes after injection, and recovery is usually 95% complete approximately 60 to 70 minutes after injection. The neuromuscular blocking action of atracurium is enhanced in the presence of potent inhalation anesthetics. Isoflurane and enflurane increase the potency of atracurium.
and prolong neuromuscular block by approximately 35%; however, halothane’s potentiating effect (approximately 20%) is marginal (see DOSAGE AND ADMINISTRATION).

Repeated administration of maintenance doses of atracurium has no cumulative effect on the duration of neuromuscular block if recovery is allowed to begin prior to repeat dosing. Moreover, the time needed to recover from repeat doses does not change with additional doses. Repeat doses can therefore be administered at relatively regular intervals with predictable results. After an initial dose of 0.4 to 0.5 mg/kg under balanced anesthesia, the first maintenance dose (suggested maintenance dose is 0.08 to 0.10 mg/kg) is generally required within 20 to 45 minutes, and subsequent maintenance doses are usually required at approximately 15 to 25 minute intervals.

Once recovery from atracurium’s neuromuscular blocking effects begins, it proceeds more rapidly than recovery from d-tubocurarine, metocurine, and pancuronium. Regardless of the atracurium dose, the time from start of recovery (from complete block) to complete (95%) recovery is approximately 30 minutes under balanced anesthesia, and approximately 40 minutes under halothane, enflurane or isoflurane. Repeated doses have no cumulative effect on recovery rate.

Atracurium besylate injection is indicated, as an adjunct to general anesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation.

CONTRAINDICATIONS
Atracurium besylate is contraindicated in patients known to have a hypersensitivity to it. Use of atracurium besylate from multiple dose vials containing benzyl alcohol as a preservative is...
WARNINGS

ATRACURIUM SHOULD BE USED ONLY BY THOSE SKILLED IN AIRWAY MANAGEMENT AND RESPIRATORY SUPPORT. EQUIPMENT AND PERSONNEL MUST BE IMMEDIATELY AVAILABLE FOR ENDOTRACHEAL INTUBATION AND SUPPORT OF VENTILATION, INCLUDING ADMINISTRATION OF POSITIVE PRESSURE OXYGEN. ADEQUACY OF RESPIRATION MUST BE ASSURED THROUGH ASSISTED OR CONTROLLED VENTILATION. ANTICHOLINESTERASE REVERSAL AGENTS SHOULD BE IMMEDIATELY AVAILABLE.

DO NOT GIVE ATRACURIUM BESYLATE BY INTRAMUSCULAR ADMINISTRATION.

Atracurium has no known effect on consciousness, pain threshold, or cerebration. It should be used only with adequate anesthesia.

Atracurium besylate injection, which has an acid pH, should not be mixed with alkaline solutions (e.g., barbiturate solutions) in the same syringe or administered simultaneously during intravenous infusion through the same needle. Depending on the resultant pH of such mixtures, atracurium may be inactivated and a free acid may be precipitated.

Atracurium besylate injection 10 mL multiple dose vials contain benzyl alcohol. In neonates, benzyl alcohol has been associated with an increased incidence of neurological and other complications which are sometimes fatal. Atracurium besylate 5 mL single use vials do not contain benzyl alcohol (see PRECAUTIONS: Pediatric Use).

Anaphylaxis: Severe anaphylactic reactions to neuromuscular blocking agents, including atracurium besylate, have been reported. These reactions have in some cases been life-threatening and fatal. Due to the potential severity of these reactions, the necessary precautions, such as the immediate availability of appropriate emergency treatment, should be taken. Precautions should also be taken in those individuals who have had previous anaphylactic reactions to other neuromuscular blocking agents since cross-reactivity between neuromuscular blocking agents, both depolarizing and non-depolarizing, has been reported in this class of drugs.

Risk of Death due to Medication Errors: Administration of atracurium besylate results in paralysis, which may lead to respiratory arrest and death; this progression may be more likely to occur in a patient for whom it is not intended. Confirm proper selection of intended product and avoid confusion with other injectable solutions that are present in critical care and other clinical settings. If another healthcare provider is administering the product, ensure that the intended dose is clearly labeled and communicated.

PRECAUTIONS

Since allergic cross-reactivity has been reported in this class, request information from your patients about previous anaphylactic reactions to other neuromuscular blocking agents. In addition, inform your patients that severe anaphylactic reactions to neuromuscular blocking agents, including atracurium besylate have been reported.

General: Although atracurium is a less potent histamine releaser than d-tubocurarine or metocurine, the possibility of substantial histamine release in sensitive individuals must be considered. Special caution should be exercised in administering atracurium to patients in whom substantial histamine release would be especially hazardous (e.g., patients with clinically significant cardiovascular disease) and in patients with any history (e.g., severe anaphylactoid reactions or asthma) suggesting a greater risk of histamine release. In these patients, the recommended initial atracurium besylate dose is lower (0.3 to 0.4 mg/kg) than for other patients and should be administered slowly or in divided doses over one minute.

Since atracurium has no clinically significant effects on heart rate in the recommended dosage range, it will not counteract the bradycardia produced by many anesthetic agents or vagal stimulation. As a result, bradycardia during anesthesia may be more common with atracurium than with other muscle relaxants.

Atracurium may have profound effects in patients with myasthenia gravis, Eaton-Lambert syndrome, or other neuromuscular diseases in which potentiation of nondepolarizing agents has been noted. The use of a peripheral nerve stimulator is especially important for assessing neuromuscular block in these patients. Similar precautions should be taken in patients with severe electrolyte disorders or carcinomatosis.

Multiple factors in anesthesia practice are suspected of triggering malignant hyperthermia (MH), a potentially fatal hypermetabolic state of skeletal muscle. Halogenated anesthetic agents and succinylcholine are recognized as the principal pharmacologic triggering agents in MH-susceptible patients; however, since MH can develop in the absence of established triggering agents, the clinician should be prepared to recognize and treat MH in any patient scheduled for general anesthesia. Reports of MH have been rare in cases in which atracurium has been used. In studies of MH-susceptible animals (swine) and in a clinical study of MH-susceptible patients, atracurium did not trigger this syndrome.

Resistance to nondepolarizing neuromuscular blocking agents may develop in burn patients. Increased contraindicated in patients with a known hypersensitivity to benzyl alcohol.
doses of nondepolarizing muscle relaxants may be required in burn patients and are dependent on the
time elapsed since the burn injury and the size of the burn.

The safety of atracurium has not been established in patients with bronchial asthma.

**Long-Term Use in Intensive Care Unit (ICU):** When there is a need for long-term mechanical
ventilation, the benefits-to-risk ratio of neuromuscular block must be considered. The long-term (1 to
10 days) infusion of atracurium besylate during mechanical ventilation in the ICU has been evaluated in
several studies. Average infusion rates of 11 to 13 mcg/kg per minute (range: 4.5 to 29.5) were required
to achieve adequate neuromuscular block. These data suggest that there is wide interpatient variability
in dosage requirements. In addition, these studies have shown that dosage requirements may decrease or
increase with time. Following discontinuation of infusion of atracurium besylate in these ICU studies,
spontaneous recovery of four twitches in a train-of-four occurred in an average of approximately 30
minutes (range: 15 to 75 minutes) and spontaneous recovery to a train-of-four ratio >75% (the ratio of
height of the fourth to the first twitch in a train-of-four) occurred in an average of approximately 60
minutes (range: 32 to 108 minutes).

Little information is available on the plasma levels and clinical consequences of atracurium metabolites
that may accumulate during days to weeks of atracurium administration in ICU patients. Laudanosine, a
major biologically active metabolite of atracurium without neuromuscular blocking activity, produces
transient hypotension and, in higher doses, cerebral excitatory effects (generalized muscle twitching
and seizures) when administered to several species of animals. There have been rare spontaneous
reports of seizures in ICU patients who have received atracurium or other agents. These patients
usually had predisposing causes (such as head trauma, cerebral edema, hypoxic encephalopathy, viral
encephalitis, uremia). There are insufficient data to determine whether or not laudanosine contributes to
seizures in ICU patients.

**WHENEVER THE USE OF ATRACURIUM OR ANY NEUROMUSCULAR BLOCKING AGENT IS
CONTEMPLATED IN THE ICU, IT IS RECOMMENDED THAT NEUROMUSCULAR
TRANSMISSION BE MONITORED CONTINUOUSLY DURING ADMINISTRATION WITH THE
HELP OF A NERVE STIMULATOR. ADDITIONAL DOSES OF ATRACURIUM OR ANY OTHER
NEUROMUSCULAR BLOCKING AGENT SHOULD NOT BE GIVEN BEFORE THERE IS A
DEFINITE RESPONSE TO T_{1} OR TO THE FIRST TWITCH. IF NO RESPONSE IS ELICITED,
INFUSION ADMINISTRATION SHOULD BE DISCONTINUED UNTIL A RESPONSE RETURNS.

Hemofiltration has a minimal effect on plasma levels of atracurium and its metabolites, including
laudanosine. The effects of hemodialysis and hemoepurification on plasma levels of atracurium and its
metabolites are unknown.

**Drug Interactions:** Drugs which may enhance the neuromuscular blocking action of atracurium include:
enflurane; isoflurane; halothane; certain antibiotics, especially the aminoglycosides and polymyxins;
lithium; magnesium salts; procainamide; and quinidine.

If other muscle relaxants are used during the same procedure, the possibility of a synergistic or
antagonist effect should be considered.

The prior administration of succinylcholine does not enhance the duration, but quickens the onset and
may increase the depth, of neuromuscular block induced by atracurium besylate. Atracurium should not
be administered until a patient has recovered from succinylcholine-induced neuromuscular block.

**Carcinogenesis, Mutagenesis, Impairment of Fertility:** Carcinogenesis and fertility studies have not
been performed. Atracurium was evaluated in a battery of three short-term mutagenicity tests. It was
non-mutagenic in both the Ames Salmonella assay at concentrations up to 1000 mcg/plate, and in a rat
bone marrow cytogenicity assay at up to paralyzing doses. A positive response was observed in the
mouse lymphoma assay under conditions (80 and 100 mcg/mL, in the absence of metabolic activation)
which killed over 80% of the treated cells; there was no mutagenicity at 60 mcg/mL and lower,
concentrations which killed up to half of the treated cells. A far weaker response was observed in the
presence of metabolic activation at concentrations (1200 mcg/mL and higher) which also killed over
80% of the treated cells.

Carcinogenesis, Mutagenesis, Impairment of Fertility: Carcinogenesis and fertility studies have not
been performed. Atracurium was evaluated in a battery of three short-term mutagenicity tests. It was
non-mutagenic in both the Ames Salmonella assay at concentrations up to 1000 mcg/plate, and in a rat
bone marrow cytogenicity assay at up to paralyzing doses. A positive response was observed in the
mouse lymphoma assay under conditions (80 and 100 mcg/mL, in the absence of metabolic activation)
which killed over 80% of the treated cells; there was no mutagenicity at 60 mcg/mL and lower,
concentrations which killed up to half of the treated cells. A far weaker response was observed in the
presence of metabolic activation at concentrations (1200 mcg/mL and higher) which also killed over
80% of the treated cells.

Mutagenicity testing is intended to simulate chronic (years to lifetime) exposure in an effort to
determine potential carcinogenicity. Thus, a single positive mutagenicity response for a drug used
infrequently and/or briefly is of questionable clinical relevance.

**Pregnancy: Teratogenic Effects:** Atracurium besylate has been shown to be potentially teratogenic in
rabbits when given in doses up to approximately one-half the human dose. There are no adequate and
well-controlled studies in pregnant women. Atracurium should be used during pregnancy only if the
potential benefit justifies the potential risk to the fetus.

Atracurium besylate was administered subcutaneously on days 6 through 18 of gestation to
nonventilated Dutch rabbits. Treatment groups were given either 0.15 mg/kg once daily or 0.10 mg/kg
twice daily. Lethal respiratory distress occurred in two 0.15 mg/kg animals and in one 0.10 mg/kg
animal, with transient respiratory distress or other evidence of neuromuscular block occurring in 10 of
19 and in 4 of 20 of the 0.15 mg/kg and 0.10 mg/kg animals, respectively. There was an increased
incidence of certain spontaneously occurring visceral and skeletal anomalies or variations in one or
both treated groups when compared to non-treated controls. The percentage of male fetuses was lower
and the post-implantation losses were increased (15% vs. 8%) in the group given 0.15 mg/kg once daily when compared to the controls; the mean numbers of implants (6.5 vs. 4.4) and normal live fetuses (5.4 vs. 3.8) were greater in this group when compared to the control group.

**Labor and Delivery:** It is not known whether muscle relaxants administered during vaginal delivery have immediate or delayed adverse effects on the fetus or increase the likelihood that resuscitation of the newborn will be necessary. The possibility that forceps delivery will be necessary may increase.

Atracurium besylate (0.3 mg/kg) has been administered to 26 pregnant women during delivery by cesarean section. No harmful effects were attributable to atracurium in any of the neonates, although small amounts of atracurium were shown to cross the placental barrier. The possibility of respiratory depression in the neonate should always be considered following cesarean section during which a neuromuscular blocking agent has been administered. In patients receiving magnesium sulfate, the reversal of neuromuscular block may be unsatisfactory and the dose of atracurium besylate should be lowered as indicated.

**Nursing Mothers:** It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when atracurium besylate is administered to a nursing woman.

**Pediatric Use:** Safety and effectiveness in pediatric patients below the age of 1 month have not been established.

**Geriatric Use:** Since marketing in 1983, uncontrolled clinical experience and limited data from controlled trials have not identified differences in effectiveness, safety, or dosage requirements between healthy elderly and younger patients (see CLINICAL PHARMACOLOGY); however, as with other neuromuscular blocking agents, the use of a peripheral nerve stimulator to monitor neuromuscular function is suggested (see DOSAGE AND ADMINISTRATION).

**ADVERSE REACTIONS**

**Observed in Controlled Clinical Studies:** Atracurium was well tolerated and produced few adverse reactions during extensive clinical trials. Most adverse reactions were suggestive of histamine release. In studies including 875 patients, atracurium was discontinued in only one patient (who required treatment for bronchial secretions) and six other patients required treatment for adverse reactions attributable to atracurium (wheezing in one, hypotension in five). Of the five patients who required treatment for hypotension, three had a history of significant cardiovascular disease. The overall incidence rate for clinically important adverse reactions, therefore, was 7/875 or 0.8%.

Table 1 includes all adverse reaction reported attributable to atracurium during clinical trials with 875 patients.

**TABLE 1: PERCENT OF PATIENTS REPORTING ADVERSE REACTIONS**

<table>
<thead>
<tr>
<th>Adverse Reaction</th>
<th>Initial Atracurium Dose (mg/kg)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0.00-0.30 (n=485)</td>
</tr>
<tr>
<td>Skin Flush</td>
<td>1.0%</td>
</tr>
<tr>
<td>Erythema</td>
<td>0.6%</td>
</tr>
<tr>
<td>Itching</td>
<td>0.4%</td>
</tr>
<tr>
<td>Wheezing/Bronchial Secretions</td>
<td>0.2%</td>
</tr>
<tr>
<td>Hives</td>
<td>0.2%</td>
</tr>
</tbody>
</table>

*Includes the recommended initial dosage range for most patients.

Most adverse reactions were of little clinical significance unless they were associated with significant hemodynamic changes. Table 2 summarizes the incidences of substantial vital sign changes noted during atracurium clinical trials with 530 patients, without cardiovascular disease, in whom these parameters were assessed.

**TABLE 2: PERCENT OF PATIENTS SHOWING >30% VITAL SIGN CHANGES FOLLOWING ADMINISTRATION OF ATRACURIUM**

<table>
<thead>
<tr>
<th>Vital Sign Change</th>
<th>Initial Atracurium Dose (mg/kg)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0.00-0.30 (n = 365)</td>
</tr>
<tr>
<td>Mean Arterial Pressure Increase</td>
<td>1.9%</td>
</tr>
<tr>
<td>Mean Arterial Pressure Decrease</td>
<td>1.1%</td>
</tr>
<tr>
<td>Heart Rate Increase</td>
<td>1.6%</td>
</tr>
<tr>
<td>Heart Rate Decrease</td>
<td>0.8%</td>
</tr>
</tbody>
</table>
Includes the recommended initial dosage range for most patients.

Observed in Clinical Practice: Based on initial clinical practice experience in approximately 3 million patients who received atracurium in the U.S. and in the United Kingdom, spontaneously reported adverse reactions were uncommon (approximately 0.01% to 0.02%). The following adverse reactions are among the most frequently reported, but there are insufficient data to support an estimate of their incidence:

**General:** Allergic reactions (anaphylactic or anaphylactoid responses) which, in rare instances, were severe (e.g., cardiac arrest)

**Musculoskeletal:** Inadequate block, prolonged block

**Cardiovascular:** Hypotension, vasodilatation (flushing), tachycardia, bradycardia

**Respiratory:** Dyspnea, bronchospasm, laryngospasm

**Integumentary:** Rash, urticaria, reaction at injection site

There have been rare spontaneous reports of seizures in ICU patients following long-term infusion of atracurium to support mechanical ventilation. There are insufficient data to define the contribution, if any, of atracurium and/or its metabolite laudanosine (See PRECAUTIONS: Long-Term Use in Intensive Care Unit [ICU]).

There have been post-marketing reports of severe allergic reactions (anaphylactic and anaphylactoid reactions) associated with use of neuromuscular blocking agents, including atracurium besylate. These reactions, in some cases, have been life-threatening and fatal. Because these reactions were reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency (see WARNINGS and PRECAUTIONS).

OVERDOSE

There has been limited experience with overdosage of atracurium besylate. The possibility of iatrogenic overdosage can be minimized by carefully monitoring muscle twitch response to peripheral nerve stimulation. Excessive doses of atracurium can be expected to produce enhanced pharmacological effects. Overdosage may increase the risk of histamine release and cardiovascular effects, especially hypotension. If cardiovascular support is necessary, this should include proper positioning, fluid administration, and the use of vasopressor agents if necessary. The patient’s airway should be assured, with manual or mechanical ventilation maintained as necessary. A longer duration of neuromuscular block may result from overdosage and a peripheral nerve stimulator should be used to monitor recovery. Recovery may be facilitated by administration of an anticholinesterase reversing agent such as neostigmine, edrophonium, or pyridostigmine, in conjunction with an anticholinergic agent such as atropine or glycopyrrolate. The appropriate package inserts should be consulted for prescribing information.

Three pediatric patients (3 weeks, 4 and 5 months of age) unintentionally received doses of 0.8 mg/kg to 1 mg/kg of atracurium besylate. The time to 25% recovery (50 to 55 minutes) following these doses, which were 5 to 6 times the ED95 dose, was moderately longer than the corresponding time observed following doses 2 to 2.5 times the atracurium ED95 dose in infants (22 to 36 minutes). Cardiovascular changes were minimal. Nonetheless the possibility of cardiovascular changes must be considered in the case of overdose.

An adult patient (17 years of age) unintentionally received an initial dose of 1.3 mg/kg of atracurium besylate. The time from injection to 25% recovery (83 minutes) was approximately twice that observed following maximum recommended doses in adults (35 to 45 minutes). The patient experienced moderate hemodynamic changes (13% increase in mean arterial pressure and 27% increase in heart rate) which persisted for 40 minutes and did not require treatment.

The intravenous LD50 determined in non-ventilated male and female albino mice and male Wistar rats were 1.9, 2.01 and 1.31 mg/kg, respectively. Deaths occurred within 2 minutes and were caused by respiratory paralysis. The subcutaneous LD50 determined in non-ventilated male Wistar rats was 282.8 mg/kg. Tremors, ptosis, loss of reflexes and respiratory failure preceded death which occurred 45 to 120 minutes after injection.

DOSAGE AND ADMINISTRATION

To avoid distress to the patient, atracurium should not be administered before unconsciousness has been induced. Atracurium should not be mixed in the same syringe, or administered simultaneously through the same needle, with alkaline solutions (e.g., barbiturate solutions).

Atracurium besylate should be administered intravenously. DO NOT GIVE ATRACURIUM BESYLATE BY INTRAMUSCULAR ADMINISTRATION. Intramuscular administration of atracurium besylate may result in tissue irritation and there are no clinical data to support this route of administration.
As with other neuromuscular blocking agents, the use of a peripheral nerve stimulator will permit the most advantageous use of atracurium besylate, minimizing the possibility of overdosage or underdosage, and assist in the evaluation of recovery.

**Bolus Doses for Intubation and Maintenance of Neuromuscular Block:**

**Adults:** An atracurium besylate dose of 0.4 to 0.5 mg/kg (1.7 to 2.2 times the ED₉₅), given as an intravenous bolus injection, is the recommended initial dose for most patients. With this dose, good or excellent conditions for nonemergency intubation can be expected in 2 to 2.5 minutes in most patients, with maximum neuromuscular block achieved approximately 3 to 5 minutes after injection. Clinically required neuromuscular block generally lasts 20 to 35 minutes under balanced anesthesia. Under balanced anesthesia, recovery to 25% of control is achieved approximately 35 to 45 minutes after injection, and recovery is usually 95% complete approximately 60 minutes after injection.

Atracurium is potentiated by isoflurane or enflurane anesthesia. The same initial atracurium besylate dose of 0.4 to 0.5 mg/kg may be used for intubation prior to administration of these inhalation agents; however, if atracurium is first administered under steady-state of isoflurane or enflurane, the initial atracurium besylate dose should be reduced by approximately one-third, i.e., to 0.25 to 0.35 mg/kg, to adjust for the potentiating effects of these anesthetic agents. With halothane, which has only a marginal (approximately 20%) potentiating effect on atracurium, smaller dosage reductions may be considered.

Atracurium besylate doses of 0.08 to 0.10 mg/kg are recommended for maintenance of neuromuscular block during prolonged surgical procedures. The first maintenance dose will generally be required 20 to 45 minutes after the initial atracurium besylate injection, but the need for maintenance doses should be determined by clinical criteria. Because atracurium lacks cumulative effects, maintenance doses may be administered at relatively regular intervals for each patient, ranging approximately from 15 to 25 minutes under balanced anesthesia, slightly longer under isoflurane or enflurane. Higher atracurium doses (up to 0.2 mg/kg) permit maintenance dosing at longer intervals.

**Pediatric Patients:** No atracurium dosage adjustments are required for pediatric patients two years of age or older. An atracurium besylate dose of 0.3 to 0.4 mg/kg is recommended as the initial dose for infants (1 month to 2 years of age) under halothane anesthesia. Maintenance doses may be required with slightly greater frequency in infants and children than in adults.

**Special Considerations:** An initial atracurium besylate dose of 0.3 to 0.4 mg/kg, given slowly or in divided doses over one minute, is recommended for adults, children, or infants with significant cardiovascular disease and for adults, children, or infants with any history (e.g., severe anaphylactoid reactions or asthma) suggesting a greater risk of histamine release.

Dosage reductions must be considered also in patients with neuromuscular disease, severe electrolyte disorders, or carcinomatosis in which potentiation of neuromuscular block or difficulties with reversal have been demonstrated. There has been no clinical experience with atracurium in these patients, and no specific dosage adjustments can be recommended. No atracurium dosage adjustments are required for patients with renal disease.

An initial atracurium besylate dose of 0.3 to 0.4 mg/kg is recommended for adults following the use of succinylcholine for intubation under balanced anesthesia. Further reductions may be desirable with the use of potent inhalation anesthetics. The patient should be permitted to recover from the effects of succinylcholine prior to atracurium administration. Insufficient data are available for recommendation of a specific initial atracurium dose for administration following the use of succinylcholine in children and infants.

**Use by Continuous Infusion:**

**Infusion in the Operating Room (OR):** After administration of a recommended initial bolus dose of atracurium besylate injection (0.3 to 0.5 mg/kg), a diluted solution of atracurium besylate can be administered by continuous infusion to adults and pediatric patients aged 2 or more years for maintenance of neuromuscular block during extended surgical procedures.

Infusion of atracurium should be individualized for each patient. The rate of administration should be adjusted according to the patient's response as determined by peripheral nerve stimulation. Accurate dosing is best achieved using a precision infusion device.

Infusion of atracurium should be initiated only after early evidence of spontaneous recovery from the bolus dose. An initial infusion rate of 9 to 10 mcg/kg/min may be required to rapidly counteract the spontaneous recovery of neuromuscular function. Thereafter, a rate of 5 to 9 mcg/kg/min should be adequate to maintain continuous neuromuscular block in the range of 89% to 99% in most pediatric and adult patients under balanced anesthesia. Occasional patients may require infusion rates as low as 2 mcg/kg/min or as high as 15 mcg/kg/min.

The neuromuscular blocking effect of atracurium administered by infusion is potentiated by enflurane or isoflurane and, to a lesser extent, by halothane. Reduction in the infusion rate of atracurium should, therefore, be considered for patients receiving inhalation anesthesia. The rate of atracurium infusion should be reduced by approximately one-third in the presence of steady-state enflurane or isoflurane anesthesia; smaller reductions should be considered in the presence of halothane.

In patients undergoing cardiopulmonary bypass with induced hypothermia, the rate of infusion of
Atracurium required to maintain adequate surgical relaxation during hypothermia (25° to 28°C) has been shown to be approximately half the rate required during normothermia.

Spontaneous recovery from neuromuscular block following discontinuation of atracurium infusion may be expected to proceed at a rate comparable to that following administration of a single bolus dose.

**Infusion in the Intensive Care Unit (ICU):** The principles for infusion of atracurium in the OR are also applicable to use in the ICU.

An infusion rate of 11 to 13 mcg/kg/min (range: 4.5 to 29.5) should provide adequate neuromuscular block in adult patients in an ICU. Limited information suggests that infusion rates required for pediatric patients in the ICU may be higher than in adult patients. There may be wide interpatient variability in dosage requirements and these requirements may increase or decrease with time (see PRECAUTIONS: Long-Term Use in Intensive Care Unit [ICU]). Following recovery from neuromuscular block, readministration of a bolus dose may be necessary to quickly reestablish neuromuscular block prior to reinstitution of the infusion.

**Infusion Rate Tables:** The amount of infusion solution required per minute will depend upon the concentration of atracurium in the infusion solution, the desired dose of atracurium, and the patient’s weight. The following tables provide guidelines for delivery, in mL/hr (equivalent to microdrops/min when 60 microdrops = 1 mL), of atracurium solutions in concentrations of 0.2 mg/mL (20 mg in 100 mL) or 0.5 mg/mL (50 mg in 100 mL) with an infusion pump or a gravity flow device.

### Table 3: Atracurium Besylate Infusion Rates for a Concentration of 0.2 mg/mL

<table>
<thead>
<tr>
<th>Patient Weight (kg)</th>
<th>Drug Delivery Rate (mcg/kg/min)</th>
<th>Infusion Delivery Rate (mL/hr)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>5</td>
<td>6</td>
</tr>
<tr>
<td>30</td>
<td>45</td>
<td>54</td>
</tr>
<tr>
<td>35</td>
<td>53</td>
<td>63</td>
</tr>
<tr>
<td>40</td>
<td>60</td>
<td>72</td>
</tr>
<tr>
<td>45</td>
<td>68</td>
<td>81</td>
</tr>
<tr>
<td>50</td>
<td>75</td>
<td>90</td>
</tr>
<tr>
<td>55</td>
<td>83</td>
<td>99</td>
</tr>
<tr>
<td>60</td>
<td>90</td>
<td>108</td>
</tr>
<tr>
<td>65</td>
<td>98</td>
<td>117</td>
</tr>
<tr>
<td>70</td>
<td>105</td>
<td>126</td>
</tr>
<tr>
<td>75</td>
<td>113</td>
<td>135</td>
</tr>
<tr>
<td>80</td>
<td>120</td>
<td>144</td>
</tr>
<tr>
<td>90</td>
<td>135</td>
<td>162</td>
</tr>
<tr>
<td>100</td>
<td>150</td>
<td>180</td>
</tr>
</tbody>
</table>

### Table 4: Atracurium Besylate Infusion Rates for a Concentration of 0.5 mg/mL

<table>
<thead>
<tr>
<th>Patient Weight (kg)</th>
<th>Drug Delivery Rate (mcg/kg/min)</th>
<th>Infusion Delivery Rate (mL/hr)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>5</td>
<td>6</td>
</tr>
<tr>
<td>30</td>
<td>18</td>
<td>22</td>
</tr>
<tr>
<td>35</td>
<td>21</td>
<td>25</td>
</tr>
<tr>
<td>40</td>
<td>24</td>
<td>29</td>
</tr>
<tr>
<td>45</td>
<td>27</td>
<td>32</td>
</tr>
<tr>
<td>50</td>
<td>30</td>
<td>36</td>
</tr>
<tr>
<td>55</td>
<td>33</td>
<td>40</td>
</tr>
<tr>
<td>60</td>
<td>36</td>
<td>43</td>
</tr>
<tr>
<td>65</td>
<td>39</td>
<td>47</td>
</tr>
<tr>
<td>70</td>
<td>42</td>
<td>50</td>
</tr>
<tr>
<td>75</td>
<td>45</td>
<td>54</td>
</tr>
<tr>
<td>80</td>
<td>48</td>
<td>58</td>
</tr>
<tr>
<td>90</td>
<td>54</td>
<td>65</td>
</tr>
<tr>
<td>100</td>
<td>60</td>
<td>72</td>
</tr>
</tbody>
</table>

**Compatibility and Admixtures:** Atracurium besylate infusion solutions may be prepared by admixing atracurium besylate injection with an appropriate diluent such as 5% Dextrose Injection, 0.9% Sodium Chloride Injection, or 5% Dextrose and 0.9% Sodium Chloride Injection. Infusion solutions should be used within 24 hours of preparation. Unused solutions should be discarded. Solutions containing 0.2 mg/mL or 0.5 mg/mL atracurium besylate in the above diluents may be stored either under refrigeration...
or at room temperature for 24 hours without significant loss of potency. Care should be taken during admixture to prevent inadvertent contamination. Visually inspect prior to administration.

Spontaneous degradation of atracurium besylate has been demonstrated to occur more rapidly in Lactated Ringer’s solution than in 0.9% sodium chloride solution. Therefore, it is recommended that Lactated Ringer’s Injection not be used as a diluent in preparing solutions of atracurium besylate injection for infusion.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

**Risk of Medication Errors:** Accidental administration of neuromuscular blocking agents may be fatal. Store atracurium besylate with the cap and ferrule intact and in a manner that minimizes the possibility of selecting the wrong product.

**HOW SUPPLIED**

Atracurium Besylate Injection USP, each mL containing 10 mg atracurium besylate, is supplied as follows:

**NDC 0409-1109-01.** 5 mL Single Dose Vial (50 mg atracurium besylate per vial). Carton of 10.

**NDC 0409-1105-02.** 10 mL Multiple Dose Vial (100 mg atracurium besylate per vial). Contains benzyl alcohol (see **WARNINGS**). Carton of 10.

Atracurium Besylate Injection should be refrigerated at 2°C to 8°C (36°F to 46°F) to preserve potency. **DO NOT FREEZE. Protect from light.** Keep vials in carton until time of use.

Upon removal from refrigeration to room temperature storage conditions (25°C/77°F), use Atracurium Besylate Injection within 14 days even if rerefrigerated.

Manufactured by:
Gland Pharma Limited;
Hyderabad 500043, India

Manufactured for:
Hospira, Inc.
Lake Forest, IL 60045 USA

M.L.No.: 103/AP/RR/97/F/R
LAB-1214-2.0
Revised: 7/2018

**PRINCIPAL DISPLAY PANEL - 10 mL Vial Label**

**NDC 0409-1105-22**

**Atracurium**
**Besylate Injection USP**

**100 mg/10 mL**
(10 mg/mL)

**WARNING: Paralyzing Agent**

**FOR INTRAVENOUS INJECTION**
Sterile, non-pyrogenic
Rx only

*Hospira*
PRINCIPAL DISPLAY PANEL - 10 mL Vial Carton

NDC 0409-1105-02
Contains 10 of NDC 0409-1105-22
10 x 10 mL Multiple Dose Vials
Atracurium Besylate Injection USP
100 mg/10 mL
(10 mg/mL)
WARNING: Paralyzing Agent
FOR INTRAVENOUS INJECTION
Sterile, non-pyrogenic
Rx only
Hospira
Atracurium Besylate Injection USP

100 mg/10 mL
(10 mg/mL)

WARNING: Paralyzing Agent

FOR INTRAVENOUS INJECTION
Sterile, non-pyrogenic

Un opened vials are stable at room temperature for 14 days if kept in unopened carton.

Each mL contains atracurium besylate, 10 mg; 0.9% benzyl alcohol (added as a preservative), and Water for Injection. Benzene sulfonyl acid added to adjust pH 3.00 to 3.65.

WARNING: Paralyzing Agent. Causes Respiratory Arrest. Facilities must be immediately available for artificial respiration.

USUAL DOSAGE: See package insert.

REFRIGERATE: Store at 2°C to 8°C (36°F to 46°F).

DO NOT FREEZE. Protect from light.

Keep vials in carton until time of use. Upon removal from refrigeration to room temperature, use within 14 days even if refrigerated.
PRINCIPAL DISPLAY PANEL - 5 mL Vial Carton

NDC 0409-1109-01
Contains 10 of NDC 0409-1109-11
10 x 5 mL Single Dose Vials
Atracurium Besylate Injection USP
50 mg/5 mL
(10 mg/mL)
WARNING: Paralyzing Agent
FOR INTRAVENOUS INJECTION
Sterile, non-pyrogenic
Rx only
Hospira
ATRACURIUM BESYLATE
atracurium besylate injection, solution

Product Information

<table>
<thead>
<tr>
<th>Product Type</th>
<th>Item Code (Source)</th>
<th>NDC: 0409-1105</th>
</tr>
</thead>
<tbody>
<tr>
<td>HUMAN PRESCRIPTION DRUG</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Route of Administration</td>
<td>INTRAVENOUS</td>
<td></td>
</tr>
</tbody>
</table>

Active Ingredient/Active Moiety

<table>
<thead>
<tr>
<th>Ingredient Name</th>
<th>Basis of Strength</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
ATRACURIUM BESYLATE
(atracurium besylate injection, solution)

**Product Information**

<table>
<thead>
<tr>
<th>Product Type</th>
<th>HUMAN PRESCRIPTION DRUG</th>
<th>Item Code (Source)</th>
<th>NDC:0409-1109</th>
</tr>
</thead>
<tbody>
<tr>
<td>Route of Administration</td>
<td>INTRAVENOUS</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Active Ingredient/Active Moiety**

<table>
<thead>
<tr>
<th>Ingredient Name</th>
<th>Basis of Strength</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>ATRACURIUM BESYLATE (UNII: 40AX66P76P) (ATRACURIUM - UNII:2GQ1IRY63P)</td>
<td>ATRACURIUM BESYLATE</td>
<td>10 mg in 1 mL</td>
</tr>
</tbody>
</table>

**Inactive Ingredients**

<table>
<thead>
<tr>
<th>Ingredient Name</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>BENZENESULFONIC ACID (UNII: 685928Z18A)</td>
<td>9 mg in 1 mL</td>
</tr>
</tbody>
</table>

**Packaging**

<table>
<thead>
<tr>
<th>#</th>
<th>Item Code</th>
<th>Package Description</th>
<th>Marketing Start Date</th>
<th>Marketing End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>NDC:0409-1105-02</td>
<td>10 in 1 CARTON</td>
<td>02/25/2013</td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>NDC:0409-1105-22</td>
<td>5 mL in 1 VIAL, SINGLE-DOSE; Type 0: Not a Combination Product</td>
<td>02/25/2013</td>
<td></td>
</tr>
</tbody>
</table>

**Marketing Information**

<table>
<thead>
<tr>
<th>Marketing Category</th>
<th>Application Number or Monograph Citation</th>
<th>Marketing Start Date</th>
<th>Marketing End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>ANDA</td>
<td>ANDA090782</td>
<td>02/25/2013</td>
<td></td>
</tr>
</tbody>
</table>

**Labeler** - Hospira, Inc. (141588017)

**Establishment**

<table>
<thead>
<tr>
<th>Name</th>
<th>Address</th>
<th>ID/FEI</th>
<th>Business Operations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gland Pharma</td>
<td>918601238</td>
<td>ANALYSIS(0409-1105, 0409-1109), MANUFACTURE(0409-1105, 0409-1109), PACK(0409-1105, 0409-1109)</td>
<td></td>
</tr>
</tbody>
</table>